Baltimore, MD | October 5-6, 2015

The Intersection of Data Privacy, Innovative Partnerships, Genetics and Ongoing Laboratory Hurdles

The Personalized/Precision Medicine Blog

The official blog of the Annual Personalized and Precision Medicine Conference provides readers with information, insight and analysis regarding the field of personalized and precision medicine, genomics, genomic interpretation and the evolution of healthcare in the post-genomic era.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Login
    Login Login form

Can Personalized Medicine Scale?

Posted by on in Uncategorized
  • Font size: Larger Smaller
  • Hits: 407
  • Subscribe to this entry
  • Print

Guest Blogger: Anya Schiess, MBA, General Partner, Co-Founder, Healthy Ventures (Ms. Schiess will be giving a presentation entitled "Healthy Ventures: A New VC Perspective" at the 7th Annual Personalized and Precision Medicine Conference in Baltimore on October 5-6, 2015.

For genomics to achieve its expected market growth, the industry will evolve from custom hardware/software/applications, where companies are almost fully vertically integrated, into an ecosystem where entrepreneurs can leverage each other’s innovations. The total amount of genome sequence data generated is doubling every 7 months and the market is expected to quintuple, to over $15 billion, by 2020 1,2. While some skeptics doubt the every day utility of genomic information, it’s difficult to argue that with so much data generated, new clinically important applications will be discovered. Commercializing new applications will require a re-organization of the industry.
As industries evolve, they often fragment. The early computer companies were vertically integrated, manufacturing everything from the processors to the software applications. As it matured, the industry fragmented into layers, and specialized companies came to dominate their layer. Early examples include Intel and microprocessors, and Microsoft and operating software. Recently, we’ve seen the same fragmentation with web infrastructure businesses, e.g. Twilio and cloud communications, AWS and cloud storage, Slack and managed collaboration. 
The genomics industry will do the same. First, we are seeing the hardware/software separation with the sequencing layer led by Illumina, and the computing layer led by AWS. Next, we will see bioinformatics fragment. For example, Spiral Genetics and data compression, DNAnexus and genome assembly, Bina (Roche) and data processing, SolveBio and the reference data layer. The companies that currently own the customer channel – like Invitae, Counsyl, and Foundation Medicine – will go from vertical integration to a focus on the application layer, outsourcing the rest of the stack. This will free tremendous working capital to focus on the new applications enabled by the data explosion. Without focusing on the new apps, these pioneers of genomic testing will be disrupted by nimbler competitors building the future. We’ll also see new categories of applications like genomic interpretation apps and pharmaceutical R&D applications. These will be built on top of an outsourced, fragmented, and more nimble stack.
At Healthy Ventures, we are investing into this fragmentation. We love companies that are creating the infrastructural backbone for the new genomics industry. We look for layers/fragments least likely to be commoditized and where the time-to-maturity is shorter; examples of which include the reference data layer. The company must have more than just a product; it must have the vision and ability to ‘own’ its layer, creating a durable business with a large absolute market, like OneCodex is doing in microbial genomics. Perhaps most difficult, the company must be relevant today, in a highly concentrated market with few end-users doing very high throughput analysis, and also relevant tomorrow in a much larger, but much more distributed market where bioinformaticists are in short supply yet everyone has access to a sequencer.
  1 Stephens, Zachary D, et al. “Big Data: Astronomical or Genomical?” PLOS Biology, 7 July 2015.
  2 Genetic testing for cancer alone is expected to be $9B. Source: Foundation Medicine.
Rate this blog entry:

John Waslif is the Managing Director of Arrowhead Publishers and Conferences and the Producer of their Annual Personalized Medicine Conference, which brings together multiple stakeholders, including payers, molecular diagnostics companies, genome analysis/interpretation companies, clinicians and many others in order to provide attendees with a holistic view of the personalized and precision medicine landscape.


  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest Wednesday, 05 August 2015

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA